- Home
- ARI vs AVTX Comparison
ARI vs AVTX Comparison
Compare ARI & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ARI | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.4M | 710.1M |
| IPO Year | 2009 | 2015 |
Fundamental Metrics
Financial Performance| Metric | ARI | AVTX |
|---|---|---|
| Price | $6.42 | $6.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $8.00 | ★ $44.08 |
| AVG Volume (30 Days) | ★ 3.3M | 2.1M |
| Earning Date | 11-02-2026 | 11-05-2026 |
| Dividend Yield | ★ 15.87% | N/A |
| EPS Growth | ★ 183.51 | 72.07 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $271,589,000.00 | $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $23.37 | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $6.11 | $6.85 |
| 52 Week High | $11.24 | $24.27 |
Technical Indicators
Market Signals| Indicator | ARI | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.99 | 17.33 |
| Support Level | $6.11 | N/A |
| Resistance Level | $6.47 | $20.54 |
| Average True Range (ATR) | 0.11 | 0.99 |
| MACD | 0.03 | -0.43 |
| Stochastic Oscillator | 84.13 | 5.34 |
Price Performance
Historical ComparisonAbout ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.